Jan Best
Overview
Explore the profile of Jan Best including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gu W, de Ledinghen V, Aube C, Krag A, Strassburg C, Castera L, et al.
NEJM Evid
. 2024 Oct;
3(11):EVIDoa2400062.
PMID: 39437136
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the...
2.
Leyh C, Coombes J, Schmidt H, Canbay A, Manka P, Best J
J Pers Med
. 2024 Apr;
14(4).
PMID: 38672997
Hepatocellular carcinoma (HCC) is a common complication of chronic liver diseases and remains a relevant cause of cancer-related mortality worldwide. The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)...
3.
Fischer A, Stippel D, Canbay A, Nierhoff D, Thomas M, Best J, et al.
Virchows Arch
. 2024 Mar;
485(2):371-377.
PMID: 38526652
We report on two cases of orthotopic liver transplantation (OLTX) due to SARS-Cov2-associated secondary sclerosing cholangitis (SSC) following long-term artificial respiration and extra-corporal membrane oxygenation in intensive care. Under these...
4.
Bellendorf A, Mader N, Mueller S, Ezziddin S, Bockisch A, Grafe H, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256934
Transarterial chemoembolization (TACE) is currently the standard of care in patients with unresectable hepatocellular carcinoma (HCC), and selective internal radionuclide therapy (SIRT) with Y microspheres is mainly used as an...
5.
Manka P, Coombes J, Sydor S, Swiderska-Syn M, Best J, Gauthier K, et al.
Liver Int
. 2023 Oct;
44(1):125-138.
PMID: 37872645
Objective: Progressive hepatic fibrosis can be considered the final stage of chronic liver disease. Hepatic stellate cells (HSC) play a central role in liver fibrogenesis. Thyroid hormones (TH, e.g. thyroxine;...
6.
Domouchtsidou A, Beckmann F, Marenbach B, Mueller S, Best J, Herrmann K, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627082
In patients with liver malignancies, the cellular immune function was impaired in vitro after selective internal radiotherapy (SIRT). Because immunosuppression varied substantially, in the current study, we investigated in 25...
7.
Kreimeyer H, Vogt K, Gotze T, Best J, Gotze O, Weigt J, et al.
J Pers Med
. 2023 Jul;
13(7).
PMID: 37511794
The prevalence of NAFLD and NASH is increasing worldwide, and there is no approved medical treatment until now. Evidence has emerged that interfering with bile acid metabolism may lead to...
8.
Broecker-Preuss M, Arzideh F, Best J, Canbay A, Ozcurumez M, Manka P
Z Gastroenterol
. 2023 Jan;
61(1):50-59.
PMID: 36623543
Background: Reference intervals for basic liver laboratory diagnostic rely on manufacturers' information, remaining unchanged for more than 20 years. This ignores known age and sex dependencies. Methods: We performed a...
9.
Sinner F, Pinter M, Scheiner B, Ettrich T, Sturm N, Gonzalez-Carmona M, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497447
Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with...
10.
Leyh C, Heucke N, Schotten C, Buchter M, Bechmann L, Wichert M, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230506
Background And Aims: Radioembolization (RE) has recently demonstrated a non-inferior survival outcome compared to systemic therapy for advanced hepatocellular carcinoma (HCC). Therefore, current guidelines recommend RE for patients with advanced...